儿童癫痫的精准治疗

石秀玉; 胡琳燕; 韩芳; 邹丽萍

doi:10.12372/jcp.2022.21e1721

临床儿科杂志 >

2022 , Vol. 40 >Issue 3: 170 - 176

DOI: https://doi.org/10.12372/jcp.2022.21e1721

专家笔谈

儿童癫痫的精准治疗

石秀玉 ,
胡琳燕 ,
韩芳 ,
邹丽萍

展开

中国人民解放军总医院儿科医学部第一医学中心儿内科(北京 100853）

石秀玉（1977—）,博士,青年编委,中国人民解放军总医院儿科医学部第一医学中心儿内科,主任医师,硕士生导师。主要从事儿童神经系统疾病的诊断和治疗,在小儿遗传代谢病和神经系统罕见病的诊断和治疗上积累了一定经验,开展儿童神经系统疾病基因检测及精准治疗。承担4项国家及省部级课题,包括2012年国家自然科学基金青年科学基金项目,2017年国家自然科学基金面上项目。获得解放军总医院医疗成果一等奖（2013-2）,军队医疗成果二等奖（2014-3）。发表论文40余篇,SCI论文25篇（第一作者21篇）。现兼任中国抗癫痫协会青年委员会委员,中华医学会儿科学分会神经学组青年委员会副组长,北京神经科学学会理事等职。

收稿日期: 2021-12-16

网络出版日期: 2022-03-09

基金资助

国家自然科学基金面上项目(81771389)

收起

Precision treatment in pediatric epilepsy

Xiuyu SHI ,
Linyan HU ,
Fang HAN ,
Liping ZOU

Expand

Department of Pediatrics, The First Medical Centre, Chinese PLA General Hospital, Beijing 100853, China

Received date: 2021-12-16

Online published: 2022-03-09

Fold

摘要

癫痫是儿童时期最常见且危害最大的神经系统疾病之一,抗癫痫药是主要的治疗方法,但在过去几十年,人们对癫痫的病因了解不多,因此主要是根据癫痫发作类型进行选药,治标不治本。近年来随着检测工具和手段的进步,越来越多的癫痫患儿能够找到癫痫病因,针对病因进行治疗能达到标本兼治的目的,儿童癫痫的治疗正步入精准治疗时代。文章根据2017年国际抗癫痫联盟新的癫痫病因分类,总结不同病因的检测方法以及相应的精准治疗,以期提高癫痫的治疗效果。

关键词： 癫痫; 儿童; 病因; 精准治疗

本文引用格式

石秀玉 , 胡琳燕 , 韩芳 , 邹丽萍 . 儿童癫痫的精准治疗[J]. 临床儿科杂志, 2022 , 40(3) : 170 -176 . DOI: 10.12372/jcp.2022.21e1721

Abstract

Epilepsy is one of the commonest and the most devastating neurological diseases in childhood, and antiepileptic drugs are the main treatment method. In the past few decades, because the causes of epilepsy were not well understood, drug selection was largely based on the type of seizure, treating only the symptoms rather than the root causes. In recent years, with new tools and means, the diagnosis of the cause of epilepsy has dramatically improved, and the treatment for the cause can achieve the purpose of treating both the symptoms and root causes. The treatment of childhood epilepsy is entering the era of precision treatment. According to the new classification of epilepsy causes published in 2017 by International League Against Epilepsy (ILAE), this paper summarizes new available tests for making diagnoses in each of the etiological categories in the ILAE classification and the corresponding precision treatment.

Key words： epilepsy; childhood; etiology; precision treatment

参考文献

[1]	Fiest KM, Sauro KM, Wiebe S, et al. Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies[J]. Neurology, 2017, 88(3): 296-303.
[2]	邓小龙, 胡春辉, 孙丹, 等. 精准药物治疗在遗传性癫痫中的应用[J]. 中国医师杂志, 2017, 19(8): 1125-1129.
[3]	臧轲君, 刘学伍, 苏永鑫, 等. 精准医学在癫痫诊疗中的临床应用进展[J]. 精准医学杂志, 2018, 33(4): 374-376.
[4]	田美玲, 谭兰. 癫痫的精准诊疗[J]. 精准医学杂志, 2018, 33(5): 377-379, 384.
[5]	Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology[J]. Epilepsia, 2017, 58(4): 522-530.
[6]	Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology[J]. Epilepsia, 2017, 58(4): 512-521.
[7]	Bowdin S, Gilbert A, Bedoukian E, et al. Recom-mendations for the integration of genomics into clinical practice[J]. Genet Med, 2016, 18(11): 1075-1084.
[8]	Wang Y, Zhou Y, Wang H, et al. Voxel-based automated detection of focal cortical dysplasia lesions using diffusion tensor imaging and T2-weighted MRI data[J]. Epilepsy Behav, 2018, 84: 127-134.
[9]	Winston GP. The potential role of novel diffusion imaging techniques in the understanding and treatment of epilepsy[J]. Quant Imaging Med Surg, 2015, 5(2): 279-287.
[10]	Moeller F, Stephani U, Siniatchkin M. Simultaneous EEG and fMRI recordings (EEG-fMRI) in children with epilepsy[J]. Epilepsia, 2013, 54(6): 971-982.
[11]	Lascano AM, Perneger T, Vulliemoz S, et al. Yield of MRI, high-density electric source imaging (HD-ESI), SPECT and PET in epilepsy surgery candidates[J]. Clin Neurophysiol, 2016, 127(1): 150-155.
[12]	Agarwal N, Krishnan B, Burgess RC, et al. Mag-netoencephalographic characteristics of cortical dysplasia in children[J]. Pediatr Neurol, 2018, 78: 13-19.
[13]	Garcia-Tarodo S, Funke M, Caballero L, et al. Mag-netoencephalographic recordings in infants: a retrospective analysis of seizure-focus yield and postsurgical outcomes[J]. J Clin Neurophysiol, 2018, 35(6): 454-462.
[14]	Holmes E, Nicholson JK, Tranter G. Metabonomic characterization of genetic variations in toxicological and metabolic responses using probabilistic neural networks[J]. Chem Res Toxicol, 2001, 14(2): 182-191.
[15]	Nicholson JK, Lindon JC, Holmes E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data[J]. Xenobiotica, 1999, 29(11): 1181-1189.
[16]	Wright CF, FitzPatrick DR, Firth HV. Paediatric genomics: diagnosing rare disease in children[J]. Nat Rev Genet, 2018, 19(5): 253-268.
[17]	Wirrell EC, Nabbout R. Recent advances in the drug treatment of Dravet syndrome[J]. CNS Drugs, 2019, 33(9): 867-881.
[18]	Wolff M, Johannesen KM, Hedrich UBS, et al. Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders[J]. Brain, 2017, 140(5): 1316-1336.
[19]	Larsen J, Carvill GL, Gardella E, et al. The phenotypic spectrum of SCN8A encephalopathy[J]. Neurology, 2015, 84(5): 480-489.
[20]	Johannesen KM, Gardella E, Encinas AC, et al. The spectrum of intermediate SCN8A-related epilepsy[J]. Epilepsia, 2019, 60(5): 830-844.
[21]	Weckhuysen S, Ivanovic V, Hendrickx R, et al. Extending the KCNQ2 encephalopathy spectrum: clinical and neuroimaging findings in 17 patients[J]. Neurology, 2013, 81(19): 1697-1703.
[22]	Millichap JJ, Park KL, Tsuchida T, et al. KCNQ2 encephalopathy: features, mutational hot spots, and ezogabine treatment of 11 patients[J]. Neurol Genet, 2016, 2(5): e96.
[23]	Striano P, Minassian BA. From genetic testing to precision medicine in epilepsy[J]. Neurotherapeutics, 2020, 17(2): 609-615.
[24]	Passey CC, Erramouspe J, Castellanos P, et al. Concurrent quinidine and phenobarbital in the treatment of a patient with 2 KCNT1 mutations[J]. Curr Ther Res Clin Exp, 2019, 90: 106-108.
[25]	Kuchenbuch M, Barcia G, Chemaly N, et al. KCNT1 epilepsy with migrating focal seizures shows a temporal sequence with poor outcome, high mortality and SUDEP[J]. Brain, 2019, 142(10): 2996-3008.
[26]	Pierson TM, Yuan H, Marsh ED, et al. GRIN2A mutation and early-onset epileptic encephalopathy: personalized therapy with memantine[J]. Ann Clin Transl Neurol, 2014, 1(3): 190-198.
[27]	Li D, Yuan H, Ortiz-Gonzalez XR, et al. GRIN2D recurrent de novo dominant mutation causes a severe epileptic encephalopathy treatable with NMDA receptor channel blockers[J]. Am J Hum Genet, 2016, 99(4): 802-816.
[28]	Daci A, Bozalija A, Jashari F, et al. Individualizing treatment approaches for epileptic patients with glucose transporter type1 (GLUT-1) deficiency[J]. Int J Mol Sci, 2018, 19(1): 122-131.
[29]	Kass HR, Winesett SP, Bessone SK, et al. Use of dietary therapies amongst patients with GLUT1 deficiency syndrome[J]. Seizure, 2016, 35: 83-87.
[30]	邹丽萍, 刘玉洁, 庞领玉, 等. 雷帕霉素治疗儿童结节性硬化症合并癫痫的临床效果及安全性观察[J]. 中华儿科杂志, 2014, 52(11): 812-816.
[31]	Dibbens LM, de Vries B, Donatello S, et al. Mutations in DEPDC5 cause familial focal epilepsy with variable foci[J]. Nat Genet, 2013, 45(5): 546-551.
[32]	Vezzani A, Fujinami RS, White HS, et al. Infections, inflammation and epilepsy[J]. Acta Neuropathol, 2016, 131(2): 211-234.
[33]	Hermetter C, Fazekas F, Hochmeister S. Systematic review: syndromes, early diagnosis, and treatment in autoimmune encephalitis[J]. Front Neurol, 2018, 9: 706.

Options

文章导航

模态框（Modal）标题

摘要

本文引用格式

Abstract

参考文献